Press Releases

GreenLight Biosciences Announces Series D Financing, Unveils RNA Strategy

MEDFORD, Mass., Sept. 13, 2017 /PRNewswire/ -- GreenLight Biosciences, Inc. announced today the completion of its $18 million Series D round of financing led by Fall Line Capital. S2G Ventures, Lewis and Clark Ventures, and Macro Capital Investments participated in the round, along with the majority of GreenLight's existing investors, including Kodiak Venture Partners, MLSCF, Syngenta Ventures and others.  GreenLight is harnessing its Cell-Free Bioprocessing® platform to develop a portfolio of RNA-based products for use in agriculture.

GreenLight Biosciences to Present at the BIO World Congress on Industrial Biotechnology

BOSTON, July 18, 2017 /PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company producing novel RNA-based products for agricultural, healthcare and other applications, today announced that management will present at the BIO World Congress on Industrial Biotechnology at the Palais des Congres in Montreal, Canada.  The presentation entitled "A novel platform for development of double-stranded RNA agricultural products" will be delivered by Dr. Andrey J. Zarur, Chairman and CEO of GreenLight, on Wednesday July 26th at 10:30 a.m. ET.